Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study reveals effectiveness of diagnostic biomarkers for canine lymphoma
The results suggest that OBD's biomarkers can be successfully translated across species for related conditions.

Results highlight potential of non-invasive biomarkers in veterinary industry

Biotechnology company Oxford BioDynamics (OBD) has announced the results of a study focused on diagnosing B-cell lymphoma in dogs. OBD is centred around discovering and developing biomarkers based on regulatory 3D genome architecture, to be used within the pharmaceutical and biotechnology industry.

The study was presented at the American Association for Cancer Research (AACR) Conference on Advances in Liquid Biopsies, and was conducted in collaboration with multiple departments from the University of Minnesota including the College of Veterinary Medicine and Masonic Cancer Centre.

According to the study, OBD utilised its proprietary datasets of markers specific for regulatory 3D genome architecture of lymphoma in humans – as defined by its EpiSwitch platform – to assess if these could be successfully translated into dogs.

Using whole blood from a group of dogs with lymphoma the company was able to generate a new biomarker signature. This signature could correctly identify dogs with and without lymphoma with 80 per cent accuracy, sensitivity and specificity, as well as 80 per cent positive and negative predictive value.

These results suggest that OBD’s biomarkers can be successfully translated across species for related conditions, and could be applied in new therapeutic developments, including within the veterinary industry.

Chief scientific officer of Oxford BioDynamics Alexandre Akoulitchev said: “Our EpiSwitch technology has provided us with a great wealth of data associated with lymphoma patients, and subsequently allowed us to translate these insights into canines, where there is a well-recognised unmet need. It is clear that the fundamentals of 3D genomics open up a new dimension for the application of [these biomarkers], particularly in veterinary science and animal welfare.”

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.